. 2014 Nov 28;6:195–204. doi: 10.2147/CPAA.S71574

Table 2.

ANOVA-derived ALA enantiomer geometric LS mean total exposure data (AUC_0–t) and the corresponding 95% CI by treatment

R-(+) AUC LS means and CI				S-(−) AUC LS means and CI			R/S AUC ratio
Treatment	Geometric mean (ng · h · mL⁻¹)	95% CI		Geometric mean (ng · h · mL⁻¹)	95% CI
Treatment	Geometric mean (ng · h · mL⁻¹)	Lower	Upper	Geometric mean (ng · h · mL⁻¹)	Lower	Upper
OS 600	3,767.7	3,279.6	4,328.5	1,713.9	1,484.1	1,979.2	2.20
T 200	2,616.5	2,180.2	3,140.2	1,277.3	1,070.6	1,523.9	2.05
T 300	2,990.3	2,601.5	3,437.1	1,468.1	1,255.2	1,717.1	2.04
T 600	2,421.8	2,043.4	2,870.3	1,156.4	952.6	1,403.9	2.09

Note: Complete study population; N=24 (12 males/12 females).

Abbreviations: ANOVA, analysis of variance; ALA, alpha-lipoic acid; LS, least squares; AUC, area under the curve; CI, confidence interval; OS, orally administered ALA solution; T 200, 200 mg tablet; T 300, 300 mg tablet; T 600, 600 mg tablet; N, number.